Huvepharma receives FDA approval for tilmicosin phosphate productHuvepharma receives FDA approval for tilmicosin phosphate product
First generic aqueous concentrate approved by FDA that controls swine respiratory disease associated with M. hyopneumoniae in presence of PRRSV.
February 11, 2022
Huvepharma has received U.S. Food and Drug Administration approval for Tilmovet AC (tilmicosin phosphate), an aqueous concentrate for the control of swine respiratory disease associated with Pasteurella multocida and Haemophilus parasuis in groups of swine in buildings where a respiratory disease outbreak is diagnosed. Tilmovet AC is also for the control of swine respiratory disease associated with Mycoplasma hyopneumoniae in the presence of porcine and respiratory syndrome virus in groups of swine in buildings where a respiratory disease outbreak is diagnosed. Comprised of the active ingredient tilmicosin phosphate, Tilmovet AC is a bio-equivalent product to Pulmotil AC.
"We are thrilled to continue our commitment of building a broad portfolio for the swine industry with the recent approval of our Tilmovet AC. This addition is complementary to our current product offering, but will also play an important role as we look to future growth of Huvepharma's swine portfolio," says Drew Weir, director of Huvepharma's Integrator Business Unit.
Tilmovet AC is the first generic aqueous concentrate approved by the FDA that controls swine respiratory disease associated with M. hyopneumoniae in the presence of PRRSV in groups of swine in buildings where a respiratory disease outbreak is diagnosed. This approval further demonstrates Huvepharma's commitment to providing producers with quality and effective choices.
"It is with great excitement that the Huvepharma swine team is bringing Tilmovet AC to the U.S. pig industry," says David Nolan, senior veterinarian on Huvepharma's swine team. "This new choice represents Huvepharma's ongoing commitment to bring solutions to the veterinarians and producers we serve. Our Tilmovet AC product will be a welcome addition to the ongoing battle against swine respiratory disease. When you have choices, you have control."
Throughout the United States, Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information, please contact your Huvepharma sales representative and/or Huvepharma's customer service team at 877-994-4883 or visit the company website.
Source: Huvepharma, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset. The opinions of this writer are not necessarily those of Farm Progress/Informa.
You May Also Like
Current Conditions for
New York, NY
Enter a zip code to see the weather conditions for a different location.
This Week in Agribusiness, December 2, 2023Dec 01, 2023
November/December National Hog FarmerDec 02, 2023
Susceptibility and transmission of rat hepatitis E virus in swineDec 01, 2023
Swine as a model for biomedical researchDec 01, 2023